| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 16,862 | 20,005 | ||
| Receivables | 20 | 20 | ||
| Prepaid expenses | 416 | 500 | ||
| Total current assets | 17,298 | 20,525 | ||
| Equipment, net | 12 | 14 | ||
| Intangible assets | 41,128 | 41,128 | ||
| Goodwill | 8,138 | 8,138 | ||
| Total assets | 66,576 | 69,805 | ||
| Trade and other payables | 1,245 | 2,315 | ||
| Total current liabilities | 1,245 | 2,315 | ||
| Derivative warrant liabilities | 201 | 1,628 | ||
| Deferred tax liability | 2,312 | 2,312 | ||
| Total liabilities | 3,758 | 6,255 | ||
| Common stock, 0.0001 par value per share 100,000,000 authorized 14,128,562 and 13,718,106 shares issued and outstanding as of september 30, 2025 and march 31, 2025, respectively | 1 | 1 | ||
| Additional paid-in capital | 293,842 | 293,636 | ||
| Accumulated other comprehensive loss | -6,038 | -6,038 | ||
| Accumulated deficit | -224,987 | -224,049 | ||
| Total stockholders' equity | 62,818 | 63,550 | ||
| Total liabilities and stockholders equity | 66,576 | 69,805 | ||
Grace Therapeutics, Inc. (GRCE)
Grace Therapeutics, Inc. (GRCE)